{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:17:57Z","timestamp":1785323877549,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12664-025-01779-3","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T21:27:52Z","timestamp":1750714072000},"page":"526-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib"],"prefix":"10.1007","volume":"45","author":[{"given":"Arshdeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshia","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanshi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmatma","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramit","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manavjot","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanisha","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6961-6389","authenticated-orcid":false,"given":"Ajit","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"1779_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/17474124.2024.2326838","volume":"18","author":"RK Pai","year":"2024","unstructured":"Pai RK, D\u2019Haens G, Kobayashi T, et al. Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials. Expert Rev Gastroenterol Hepatol. 2024;18:73\u201387. https:\/\/doi.org\/10.1080\/17474124.2024.2326838.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"1779_CR2","doi-asserted-by":"publisher","unstructured":"Jairath V, Zou G, Wang Z, et al. Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial. BMJ Open Gastroenterol. 2024;11:e001218. https:\/\/doi.org\/10.1136\/bmjgast-2023-001218.","DOI":"10.1136\/bmjgast-2023-001218"},{"key":"1779_CR3","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology."},{"key":"1779_CR4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1606910.","journal-title":"N Engl J Med."},{"key":"1779_CR5","doi-asserted-by":"publisher","unstructured":"Sandborn WJ, Lawendy N, Danese S, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022;55:464\u201378. https:\/\/doi.org\/10.1111\/apt.16712.","DOI":"10.1111\/apt.16712"},{"key":"1779_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ibd\/izab011","volume":"28","author":"C Taxonera","year":"2022","unstructured":"Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022;28:32\u201340. https:\/\/doi.org\/10.1093\/ibd\/izab011.","journal-title":"Inflamm Bowel Dis."},{"key":"1779_CR7","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s10620-019-05492-y","volume":"64","author":"R Weisshof","year":"2019","unstructured":"Weisshof R, Aharoni Golan M, Sossenheimer PH, et al. Real-world experience with tofacitinib in IBD at a tertiary center. Dig Dis Sci. 2019;64:1945\u201351. https:\/\/doi.org\/10.1007\/s10620-019-05492-y.","journal-title":"Dig Dis Sci."},{"key":"1779_CR8","doi-asserted-by":"publisher","unstructured":"Cremer A, Lobaton T, Vieujan S, et al. P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study. J Crohns Colitis. 2020;14 Supplement_1:S384\u20136. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz203.551.","DOI":"10.1093\/ecco-jcc\/jjz203.551"},{"key":"1779_CR9","doi-asserted-by":"publisher","first-page":"13863","DOI":"10.1038\/s41598-023-41137-x","volume":"13","author":"N Nakamura","year":"2023","unstructured":"Nakamura N, Honzawa Y, Nishimon S, et al. Combined serum albumin, fecal immunochemical test, and leucine-rich alpha-2 glycoprotein levels for predicting prognosis in remitting patients with ulcerative colitis. Sci Rep. 2023;13:13863. https:\/\/doi.org\/10.1038\/s41598-023-41137-x.","journal-title":"Sci Rep."},{"issue":"Suppl 1","key":"1779_CR10","doi-asserted-by":"publisher","first-page":"i713","DOI":"10.1093\/ecco-jcc\/jjac190.0715","volume":"17","author":"S Vermeire","year":"2023","unstructured":"Vermeire S, Abraham B, Bressler B, et al. P585 Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study. J Crohns Colitis. 2023;17(Suppl 1):i713\u2013i74. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.0715.","journal-title":"J Crohns Colitis."},{"key":"1779_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/ecco-jcc\/jjv158","volume":"10","author":"M Barreiro-de Acosta","year":"2016","unstructured":"Barreiro-de Acosta M, Vallejo N, de la Iglesia D, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study. J Crohns Colitis. 2016;10:13\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv158.","journal-title":"J Crohns Colitis."},{"key":"1779_CR12","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(23)00061-2.","journal-title":"Lancet."},{"key":"1779_CR13","doi-asserted-by":"publisher","unstructured":"Singh A, Bhardwaj A, Sharma R, et al. Predictive accuracy of fecal calprotectin for histologic remission in ulcerative colitis.\u00a0\u00a0Intest Res. 2025;23:144-56. https:\/\/doi.org\/10.5217\/ir.2024.00068","DOI":"10.5217\/ir.2024.00068"},{"key":"1779_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ibd\/izac170","volume":"29","author":"A Sood","year":"2023","unstructured":"Sood A, Singh A, Mahajan R, Midha V, Bernstein CN, Rubin DT. (Re)Appraising remission in ulcerative colitis. Inflamm Bowel Dis. 2023;29:1317\u201326. https:\/\/doi.org\/10.1093\/ibd\/izac170.","journal-title":"Inflamm Bowel Dis."},{"key":"1779_CR15","doi-asserted-by":"publisher","unstructured":"Shehab M, Hassan A, Alrashed F, et al. Comparative efficacy of biologics and small molecule therapies in improving patient-reported outcomes in ulcerative colitis: systematic review and network meta-analysis.\u00a0Inflamm Bowel Dis. 2025;31:1272-80. https:\/\/doi.org\/10.1093\/ibd\/izae163","DOI":"10.1093\/ibd\/izae163"},{"key":"1779_CR16","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00666-8.","journal-title":"Lancet."},{"key":"1779_CR17","unstructured":"TREMFYA\u00ae (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission. JNJ.com. May 20, 2024. Accessed September 12, 2024. https:\/\/www.jnj.com\/media-center\/press-releases\/tremfya-guselkumab-quasar-maintenance-study-in-uc-met-its-primary-endpoint-and-all-major-secondary-endpoints-including-highly-statistically-significant-rates-of-endoscopic-remission"},{"key":"1779_CR18","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2207940.","journal-title":"N Engl J Med."},{"key":"1779_CR19","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D\u2019Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385:1280\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2033617.","journal-title":"N Engl J Med."},{"key":"1779_CR20","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(22)00581-5.","journal-title":"Lancet."},{"key":"1779_CR21","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1053\/j.gastro.2020.08.037","volume":"159","author":"K Li","year":"2020","unstructured":"Li K, Marano C, Zhang H, et al. Relationship between combined histologic and endoscopic endpoints and efficacy of ustekinumab treatment in patients with ulcerative colitis. Gastroenterology. 2020;159:2052\u201364. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.037.","journal-title":"Gastroenterology."},{"key":"1779_CR22","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","volume":"161","author":"L Peyrin-Biroulet","year":"2021","unstructured":"Peyrin-Biroulet L, Loftus EV, Colombel JF, et al. Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of vedolizumab intravenous compared to adalimumab subcutaneous in participants with ulcerative colitis (VARSITY). Gastroenterology. 2021;161:1156\u201367.e3. https:\/\/doi.org\/10.1053\/j.gastro.2021.06.015.","journal-title":"Gastroenterology."},{"key":"1779_CR23","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","volume":"17","author":"V Solitano","year":"2023","unstructured":"Solitano V, Vuyyuru SK, MacDonald JK, et al. Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis. J Crohns Colitis. 2023;17:1800\u201316. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad100.","journal-title":"J Crohns Colitis."},{"key":"1779_CR24","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/ecco-jcc\/jjae031","volume":"18","author":"S van Gennep","year":"2024","unstructured":"van Gennep S, Fung ICN, de Jong DC, et al. Histological outcomes and JAK-STAT signalling in ulcerative colitis patients treated with tofacitinib. J Crohns Colitis. 2024;18:1283\u201391. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae031.","journal-title":"J Crohns Colitis."},{"key":"1779_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/apt.16955","volume":"56","author":"B Verstockt","year":"2022","unstructured":"Verstockt B, Volk V, Jaeckel C, et al. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Aliment Pharmacol Ther. 2022;56:282\u201391. https:\/\/doi.org\/10.1111\/apt.16955.","journal-title":"Aliment Pharmacol Ther."},{"key":"1779_CR26","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s10620-022-07716-0","volume":"68","author":"NA Cohen","year":"2023","unstructured":"Cohen NA, Steinberg JM, Silfen A, et al. Endo-histologic normalization is achievable with tofacitinib and is associated with improved clinical outcomes. Dig Dis Sci. 2023;68:1464\u201372. https:\/\/doi.org\/10.1007\/s10620-022-07716-0.","journal-title":"Dig Dis Sci."},{"key":"1779_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.dld.2023.11.022","volume":"56","author":"S Vieujean","year":"2024","unstructured":"Vieujean S, Laharie D, Buisson A, et al. Histological healing induced by tofacitinib in ulcerative colitis: a multicentre study. Dig Liver Dis. 2024;56:613\u201321. https:\/\/doi.org\/10.1016\/j.dld.2023.11.022.","journal-title":"Dig Liver Dis."},{"key":"1779_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/apt.17305","volume":"57","author":"A Buisson","year":"2023","unstructured":"Buisson A, Nachury M, Guilmoteau T, et al. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Aliment Pharmacol Ther. 2023;57:676\u201388. https:\/\/doi.org\/10.1111\/apt.17305.","journal-title":"Aliment Pharmacol Ther."},{"key":"1779_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.dld.2019.10.003","volume":"52","author":"L Lair-Mehiri","year":"2020","unstructured":"Lair-Mehiri L, Stefanescu C, Vaysse T, et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020;52:268\u201373. https:\/\/doi.org\/10.1016\/j.dld.2019.10.003.","journal-title":"Dig Liver Dis."},{"key":"1779_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","volume":"21","author":"T Straatmijer","year":"2023","unstructured":"Straatmijer T, Biemans VBC, Visschedijk M, et al. Superior effectiveness of tofacitinib compared to vedolizumab in anti-tnf-experienced ulcerative colitis patients: a nationwide Dutch registry study. Clin Gastroenterol Hepatol. 2023;21:182\u201391.e2. https:\/\/doi.org\/10.1016\/j.cgh.2022.04.038.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1779_CR31","doi-asserted-by":"publisher","unstructured":"Ma C, Panaccione R, Xiao Y, et al. REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD research consortium multicenter national cohort study.\u00a0Am J Gastroenterol. 2023;118:861\u201371.\u00a0https:\/\/doi.org\/10.14309\/ajg.0000000000002129.","DOI":"10.14309\/ajg.0000000000002129"},{"key":"1779_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5217\/ir.2023.00194","volume":"22","author":"H Shimizu","year":"2024","unstructured":"Shimizu H, Aonuma Y, Hibiya S, et al. Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study. Intest Res. 2024;22:369\u201377. https:\/\/doi.org\/10.5217\/ir.2023.00194.","journal-title":"Intest Res."},{"key":"1779_CR33","doi-asserted-by":"publisher","unstructured":"Chaparro M, Acosta D, Rodr\u00edguez C, et al. Real-world evidence of tofacinitib in ulcerative colitis: short-term and long-term effectiveness and safety. Am J Gastroenterol. 2023;118:1237\u201347. https:\/\/doi.org\/10.14309\/ajg.0000000000002145.","DOI":"10.14309\/ajg.0000000000002145"},{"key":"1779_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ecco-jcc\/jjad153","volume":"18","author":"A Singh","year":"2024","unstructured":"Singh A, Midha V, Kaur K, et al. Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis [ORCHID]: a prospective, open-label, randomized, pilot study. J Crohns Colitis. 2024;18:300\u20137. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad153.","journal-title":"J Crohns Colitis."},{"key":"1779_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12664-023-01507-9","volume":"43","author":"R Banerjee","year":"2024","unstructured":"Banerjee R, Sharma V, Patel R, et al. Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice. Indian J Gastroenterol. 2024;43:22\u201335. https:\/\/doi.org\/10.1007\/s12664-023-01507-9.","journal-title":"Indian J Gastroenterol."},{"key":"1779_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12664-023-01434-9","volume":"43","author":"S Giri","year":"2024","unstructured":"Giri S, Bhrugumalla S, Kamuni A, et al. Upfront tofacitinib in patients with biological-na\u00efve ulcerative colitis - An Indian multicentric experience. Indian J Gastroenterol. 2024;43:237\u201343. https:\/\/doi.org\/10.1007\/s12664-023-01434-9.","journal-title":"Indian J Gastroenterol."},{"key":"1779_CR37","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10620-024-08276-1","volume":"69","author":"A Singh","year":"2024","unstructured":"Singh A, Mahajan R, Midha V, et al. Effectiveness of tofacitinib in ulcerative proctitis compared to left sided colitis and pancolitis. Dig Dis Sci. 2024;69:1389\u2013402. https:\/\/doi.org\/10.1007\/s10620-024-08276-1.","journal-title":"Dig Dis Sci."}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-025-01779-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-025-01779-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-025-01779-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:32:41Z","timestamp":1778484761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-025-01779-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1779"],"URL":"https:\/\/doi.org\/10.1007\/s12664-025-01779-3","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ajit Sood is on the advisory board of Janssen Pharmaceuticals (Asia\u2013Pacific) and received honorarium for speaker events from Pfizer India and Takeda India. ArS,\u00a0AB, DJ, RS, DS, RM, KK, AS, VN, HK, MS, PG, TS and VM\u00a0disclose no conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The\u00a0study was performed conforming to the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and\u00a0animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology\u00a0or the printer\/publishers are responsible for the results\/findings and content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}